These findings indicated that the immune checkpoint signaling axis contributed to immune escape in EBV+ AR‐NHL, highlighting the potential therapeutic value of targeting the PD‐1/PD‐L1 pathway in this rare subset. This evidence concerns the gene PDCD1 and non-Hodgkin lymphoma.